Last reviewed 2026-05-22 · How we verify

Phencarol (QUIFENADINE)

Phase 2 active Small molecule ✓ Verified May 2026

Phencarol (generic name: QUIFENADINE) is a quifenadine drug. It is currently in Phase 2 development for Allergic conjunctivitis, Allergic rhinitis, Seasonal allergic rhinitis.

Phencarol works by blocking the action of histamine, a chemical released by the body during an allergic reaction.

Phencarol is a small molecule. It is also known by the synonyms QUIFENADINA, QUIFENADINE, and QUIFENADINE.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	QUIFENADINE
Drug class	quifenadine
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Imagine your body's immune system is like a fire alarm that goes off when it senses something foreign. Histamine is like the loud siren that alerts you to the presence of the foreign substance. Phencarol silences the siren, reducing the symptoms of an allergic reaction.

Approved indications

Allergic conjunctivitis
Allergic rhinitis
Seasonal allergic rhinitis
Sneezing

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Phencarol CI brief — competitive landscape report
Phencarol updates RSS · CI watch RSS

Frequently asked questions about Phencarol

What is Phencarol?

Phencarol (QUIFENADINE) is a quifenadine drug, indicated for Allergic conjunctivitis, Allergic rhinitis, Seasonal allergic rhinitis.

How does Phencarol work?

Phencarol works by blocking the action of histamine, a chemical released by the body during an allergic reaction.

What is Phencarol used for?

Phencarol is indicated for Allergic conjunctivitis, Allergic rhinitis, Seasonal allergic rhinitis, Sneezing.

What is the generic name of Phencarol?

QUIFENADINE is the generic (nonproprietary) name of Phencarol.

What drug class is Phencarol in?

Phencarol belongs to the quifenadine class. See all quifenadine drugs at /class/quifenadine.

What development phase is Phencarol in?

Phencarol is in Phase 2.

Drug class: All quifenadine drugs
Therapeutic area: All drugs in Immunology
Indication: Drugs for Allergic conjunctivitis
Indication: Drugs for Allergic rhinitis
Indication: Drugs for Seasonal allergic rhinitis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing